Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Monopar Therapeutics Inc.NASDAQ: MNPR

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$93.4M, compared with -$78.42M a year earlier.

Context

  • Retained earnings amounted to 67.7% of total assets at the end of Q1 FY2026, down 74.7 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -19.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$93.4M-4.3% QoQ
Last fiscal yearDec 2025
-$89.51M-18.1% YoY
Year agoMar 2025
-$78.42M-19.1% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.1%——
1 year-18.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(89.51M) USD
Year-over-year change
-18.1%

Retained Earnings vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -19.1% is the 8th highest of 11, against a peer median of -13.8%.
  • Retained earnings amounts to 67.7% of total assets for MNPR, versus a peer median of 317.2%.
MNPR Competitors
Retained Earnings for MNPR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MNPRMonopar Therapeutics Inc.Mar 2026-$93.4M USD-19.1%—67.7%
ATNMActinium Pharmaceuticals, Inc.Jun 2026-$387.33M USD+2.8%—964.5%
IPHAInnate Pharma S.A.Dec 2025-€435.36M EUR-12.7%—694.4%
CMPXCompass Therapeutics, Inc.Mar 2026-$449.49M USD-17.9%—219.1%
ALXOALX Oncology Holdings Inc.Mar 2026-$740.74M USD-13.6%—415.4%
IMNMImmunome, Inc.Sep 2026-$940.91M USD-42.9%—186.1%
XNCRXencor, Inc.Jun 2026-$946.6M USD-20.9%—130.6%
BCYCBicycle Therapeutics plcMar 2026-$960.58M USD-29.5%—147.2%
ZYMEZymeworks Inc.Sep 2026-$1.01B USD-13.9%—85.8%
MGNXMacroGenics, Inc.Mar 2026-$1.28B USD-5.8%—588.0%
ADCTADC Therapeutics S.A.Mar 2026-$1.67B USD-8.9%—572.5%
Peer median (excluding MNPR) —-13.8%—317.2%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents20.3M8.19M7.27M45.82M61.83M
Short-term Investments04.93M014.4M78.57M
Net Receivables00000
Inventory00000
Other Current Assets217.75K45.98K66.43K78.87K63.75K
Total Current Assets20.52M13.17M7.33M60.29M140.46M
Property, Plant & Equipment (Net)061.23K12.65K0254.92K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets061.23K12.65K0254.92K
Total Assets20.52M13.23M7.35M60.29M140.72M
Account Payables1.58M3.13M1.76M2.25M2.74M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities1.58M3.13M1.76M5.25M2.74M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities08.41K00154.92K
Total Liabilities1.58M3.14M1.76M5.25M2.89M
Common Stock12.6K12.95K14.91K6.1K6.69K
Retained Earnings(41.29M)(51.8M)(60.21M)(75.79M)(89.51M)
Accumulated OCI(3.16K)8.94K(14.13K)35.99K131.39K
Other Stockholders Equity00000
Minority Interest00000
Total Equity18.94M10.09M5.59M55.04M137.83M
Total Debt08.41K00154.92K
Net Debt(20.3M)(8.18M)(7.27M)(45.82M)(61.68M)

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.